TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06152757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: First dose
Description: 1.0×10\^8cells,Intravenous infusion，1 subject is planned to be enrolled

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Second dose
Description: 3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The third dose
Description: 1.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The fourth dose
Description: 3.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
Study: NCT05069454

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine Observation of individuals who receive the COVID-19 vaccine
Description: To measure the effectiveness of COVID-19 vaccines against symptomatic laboratory-confirmed SARS-CoV-2 infection amongst hospital level health workers eligible for vaccination.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine Observation of individuals who receive the COVID-19 vaccine
Description: To measure the effectiveness of COVID-19 vaccines against symptomatic laboratory-confirmed SARS-CoV-2 infection amongst hospital level health workers eligible for vaccination.
Study: NCT06050668

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Essential Amino Acid Supplementation
Description: Powdered supplement that can be mixed into beverage of choice. Ingredients: Zinc, Vitamin A, Vitamin C, Whey Protein, Leucine, Calcium, Vitamin D, Glutamine, Boron, Turmeric, Bioperine, Iron, β-hydroxy β-methylbutyrate (HMB)
Study: NCT05270902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb Adsorber
Description: Polymer based adsorber system for the elimination of cytokines
Study: NCT05402566

Intervention type: DIAGNOSTIC_TEST
Intervention: Deuterium metabolic imaging
Description: MRI after oral administration of 75g of \[6,6'-2H2\]glucose.

Intervention type: DIAGNOSTIC_TEST
Intervention: Deuterium metabolic imaging
Description: MRI after oral administration of 75g of \[6,6'-2H2\]glucose.

Intervention type: DIAGNOSTIC_TEST
Intervention: Deuterium metabolic imaging
Description: MRI after oral administration of 75g of \[6,6'-2H2\]glucose.
Study: NCT06188039

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Superior vena cava collapsibility index
Description: After induction of general anaesthesia following interventions will be performed.~1. Insertion of a tranesophageal echocardiography probe~2. Measurement of SVC-CI~3. Measurement of LVOT-VTI prior to fluid bolus~4. Fluid bolus (250ml of crystalloid)~5. Measurement of LVOT-VTI after fluid bolus~Several volume trials per patient will be allowed, until safety criteria are met. In such cases further testing will be stopped.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Superior vena cava collapsibility index
Description: After induction of general anaesthesia following interventions will be performed.~1. Insertion of a tranesophageal echocardiography probe~2. Measurement of SVC-CI~3. Measurement of LVOT-VTI prior to fluid bolus~4. Fluid bolus (250ml of crystalloid)~5. Measurement of LVOT-VTI after fluid bolus~Several volume trials per patient will be allowed, until safety criteria are met. In such cases further testing will be stopped.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Superior vena cava collapsibility index
Description: After induction of general anaesthesia following interventions will be performed.~1. Insertion of a tranesophageal echocardiography probe~2. Measurement of SVC-CI~3. Measurement of LVOT-VTI prior to fluid bolus~4. Fluid bolus (250ml of crystalloid)~5. Measurement of LVOT-VTI after fluid bolus~Several volume trials per patient will be allowed, until safety criteria are met. In such cases further testing will be stopped.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP elevation
Description: A transient elevation of positive end-expiratory pressure (PEEP) will be applied, in order to validate SVC-CI in the setting of elevated PEEP.~A PEEP level of 8-10cmH2O will be applied for 1 minute prior to every measurement of SVC-CI. Then the previous PEEP level will be reinstated.
Study: NCT04891510

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REVOLVE Advanced Adipose System
Description: The REVOLVE system is an all-in-one fat processing device that harvests, filters, actively washes, and removes strands from lipoaspirate and allows for reinjection without any additional manipulation (REVOLVE 2020).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LipoGrafter
Description: The LipoGrafter system is designed to be a start-to-finish closed system with minimal processing of the lipoaspirate, minimizing the risk of contamination and fat cell damage (LipoGrafter 2020).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Viality
Description: The Viality system uses the AuraClens solution that acts as a surfactant to bring impurities like blood, free oil, and cellular debris into solution, where they can be flushed out through suction.
Study: NCT05968118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NL003
Description: Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections ) Other Name: Placebo
Study: NCT05743439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Augmentative and Alternative Communication (AAC) Intervention
Description: Caregivers will receive 24, 50 min intervention sessions twice a week for three months. During each intervention session, the therapist provides instruction and coaching on using AAC and a set of evidence-based language support strategies. Strategies are taught sequentially in three phases: (1) Responding to all Communication, (2) Teaching Words, and (3) Creating Communication Opportunities. Caregivers practice using the AAC intervention strategies during three, five-minute routines with their children. Therapists coach the caregiver on using the targeted strategies during these routines, encouraging caregivers to reflect on their implementation, and developing a plan to use the AAC strategies during activities not practiced during the intervention session. The AAC intervention is provided to families using an evidence-based service delivery model, Family Guided Routines Based Intervention.
Study: NCT05413356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Oral ruxolitinib twice daily
Study: NCT05174351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: beta blocker discontinuation
Description: beta blocker discontinuation
Study: NCT05822284

Intervention type: DIAGNOSTIC_TEST
Intervention: NGS and ctDNA-MRD detection
Description: NGS and ctDNA-MRD detection
Study: NCT05810688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eating rehabilitation training
Description: The experimental group will receive eating rehabilitation training, including oral care, saliva gland massage, oral exercise, feeding strategy, and swallowing skill education.
Study: NCT04682522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral
Description: 250 mg Three times a day
Study: NCT04490616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rTMS treatment
Description: A two-site rTMS stimulation delivered by a Magstim unit featuring a double 70 mm cooled coil will be applied.~MCI patients will be randomly assigned to one of the two study groups:~1. RR-Gr will receive 4 weeks of rTMS stimulation of the right temporo-parietal junction (RTPJ) and medial prefrontal cortex (MPFC);~2. PL-Gr will receive sham stimulation of the RTPJ and MPFC during the first 2 weeks followed by 2 weeks of real stimulation. Each week of rTMS treatment will consist of five sessions (50 min, one per day).~For each area target, a total of 2000 pulses at 20Hz, 3-s train duration, and 28-s inter-train interval at 100% motor threshold (MT) will be delivered per session. A fixed intensity of MT will ensure a more consistent spatial spread of TMS effects in subjects' brains not influenced by differences in individual MT. In the sham condition, a sham coil will be used.~Each session lasted for about 60 min including time for set up and 50 min of stimulation.

Intervention type: OTHER
Group type: OTHER
Intervention: rTMS treatment
Description: A two-site rTMS stimulation delivered by a Magstim unit featuring a double 70 mm cooled coil will be applied.~MCI patients will be randomly assigned to one of the two study groups:~1. RR-Gr will receive 4 weeks of rTMS stimulation of the right temporo-parietal junction (RTPJ) and medial prefrontal cortex (MPFC);~2. PL-Gr will receive sham stimulation of the RTPJ and MPFC during the first 2 weeks followed by 2 weeks of real stimulation. Each week of rTMS treatment will consist of five sessions (50 min, one per day).~For each area target, a total of 2000 pulses at 20Hz, 3-s train duration, and 28-s inter-train interval at 100% motor threshold (MT) will be delivered per session. A fixed intensity of MT will ensure a more consistent spatial spread of TMS effects in subjects' brains not influenced by differences in individual MT. In the sham condition, a sham coil will be used.~Each session lasted for about 60 min including time for set up and 50 min of stimulation.
Study: NCT05767320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open repair(exploration)
Description: repair of defect of perforated peptic ulcer and peritoneal decontamination by exploration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal laparoscopy
Description: repair of defect of perforated peptic ulcer and peritoneal decontamination by laparoscopy
Study: NCT06158555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 ML NaCl 4.5 MG/ML Injection
Description: Bolus 250 ml crystalloid. Usually 0.9% saline or compound sodium lactate solution at discretion of attending clinician
Study: NCT05790902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: The patients used Silodosin for Medical expulsive therapy of ureteric calculi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: The patients used Tamsulosin for Medical expulsive therapy of ureteric calculi
Study: NCT05499689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 2.5 cc bupivacain injection will be administered by approaching the greater occipital nerve under ultrasound guidance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous pulsed radiofrequency qurrent
Description: Pulsed radiofrequency current will be applied through transcutaneous pads adhered over the greater occipital nerve trace on the nape.
Study: NCT05119244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood and hair sampling
Description: 3.5 ml blood sample Hair sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood and hair sampling
Description: 3.5 ml blood sample Hair sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood and hair sampling
Description: 3.5 ml blood sample Hair sample
Study: NCT01596413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sancuso
Description: granisetron transdermal system

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV granisetron
Description: IV
Study: NCT05864196

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Two-Fraction Stereotactic Body Radiation Therapy (SBRT)
Description: Two-fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer.
Study: NCT05476900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR19042 Capsules
Description: HR19042 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR19042 Capsules
Description: HR19042 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR19042 Capsules
Description: HR19042 Capsules
Study: NCT05445349

Intervention type: DEVICE
Intervention: Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy
Description: The DPI inhaler devices are empty, without any active ingredient or/and carrier substances. Patients are not inhaling drug doses because of the study. They are inhaling only the type and quantity of aerosol drugs that they would inhale because of their treatment. The study does not influences the undergoing treatment by medication in any way.

Intervention type: DEVICE
Intervention: Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy
Description: The DPI inhaler devices are empty, without any active ingredient or/and carrier substances. Patients are not inhaling drug doses because of the study. They are inhaling only the type and quantity of aerosol drugs that they would inhale because of their treatment. The study does not influences the undergoing treatment by medication in any way.
Study: NCT05181735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept Injection [Reblozyl]
Description: All patients will receive Luspatercept subcutaneously on day 1 of each 21 day cycle (every 3 weeks) at the selected dose according to part A : 1.75mg/kg or 1.33 mg/kg or 0.8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept Injection [Reblozyl]
Description: All patients will receive Luspatercept subcutaneously on day 1 of each 21 day cycle (every 3 weeks) at the selected dose according to part A : 1.75mg/kg or 1.33 mg/kg or 0.8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprex
Description: Epoietin alfa will be adminstered as a subcutaneous injection at the selected dose according to part A : 30 000 UI/week or 60 000 UI/week, every week
Study: NCT06261905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C]-PHNO
Description: PHNO is used as a tracer for in-vivo imaging.
Study: NCT05481619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab
Description: Recommended dose in patients with UC: 300 mg intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter.~Discontinue vedolizumab at week 14 in patients who do not show treatment benefit.
Study: NCT04790513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: anti-PCSK9 small binding protein

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: evolocumab
Description: monoclonal antibody to PCSK9

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: alirocumab
Description: monoclonal antibody to PCSK9
Study: NCT05785884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Description: A 6 week randomized diet low in carbohydrates

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Description: A 6 week randomized diet low in carbohydrates

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: USDA Diet
Description: A 6 week randomized diet aligned with USDA recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: USDA Diet
Description: A 6 week randomized diet aligned with USDA recommendations
Study: NCT06413511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belantamab
Description: Belantamab will be administered.
Study: NCT05682651

Intervention type: PROCEDURE
Intervention: tracheal stenosis follow-up file
Description: Patients' age, gender, American Society of Anesthesiologists (ASA) classification, comorbidities, etiologic cause, intubation time, type of surgery, length of hospital stay, and morbidity/mortality information will be recorded.

Intervention type: PROCEDURE
Intervention: tracheal stenosis follow-up file
Description: Patients' age, gender, American Society of Anesthesiologists (ASA) classification, comorbidities, etiologic cause, intubation time, type of surgery, length of hospital stay, and morbidity/mortality information will be recorded.
Study: NCT04014140

Intervention type: PROCEDURE
Intervention: Coronary artery bypass grafting surgery (CABG)
Description: Patients with MVCAD will undergo CABG as per standard of care.
Study: NCT05804630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)
Description: As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)
Description: As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)
Description: As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)
Description: As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.
Study: NCT05747482

Intervention type: OTHER
Group type: OTHER
Intervention: Surgery procedure
Description: Omentectomy vs omental preservations during gastric surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Surgery procedure
Description: Omentectomy vs omental preservations during gastric surgery
Study: NCT06078111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prism 10 + visuo-motor activities
Description: Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with 10 degrees of visual field deviation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Prism + visuo-motor activities
Description: Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with no visual field deviation
Study: NCT06261905

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [11C]-PHNO
Description: PHNO is used as a tracer for in-vivo imaging.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Calcitriol is an active form of Vitamin D and is given in 3 0.5mcg capsules per dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: A placebo is an inert capsule, which contains no active ingredients. The placebo will be given in 3 0.5mcg capsules per dose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PET Scan
Description: A high resolution PET Scan performed using a NeurExplorer CT scanner.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PET Scan
Description: A high resolution PET Scan performed using a NeurExplorer CT scanner.
Study: NCT05605132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Training Exercise
Description: oculomotor exercises will be applied to the participants three times a week for four weeks.~oculomotor exercises:~* head relocation~* gaze stability~* eye follow~* saccadic eye movement~* head and eye coordination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile Acuity Training
Description: Participants will be requested to lie face down. Five points will be marked in the painful areas on the right and left sides of the neck. The distance between the points will equal the two-point discrimination value. A photograph of the neck will be taken. The patient will not see his/her own neck during the application but see the photograph of his/her neck. The points will be touched lightly with two different stimuli (a pen with a 2 mm diameter and a mushroom probe with an 11 mm diameter). Participants will be asked about the location and type of the stimuli. The interstimulus interval will be 15 seconds. If more than 90% of correct answers are obtained, the distance between the points will be reduced by 10%. The training will be performed in three separate blocks, a total of 72 stimuli (block duration = 6 minutes, rest time between blocks = 3 minutes, number of stimuli applied in each block = 24 stimuli). The treatment time will be 24 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: The participants will be evaluated two times at 4-week intervals. No intervention will be applied during the time frame.
Study: NCT05870995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CALGE-VEN- RIC-conditioning
Description: Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation
Study: NCT05514184

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PLAFOND diet
Description: PLAFOND is a pragmatic patient-centered dietary intervention supported by dietitians who provide education and counseling in the form of Medical Nutrition Therapy (MNT) consisting of 0.6-0.8 g/kg/day dietary protein with \>2/3% of the protein from plant-proteins.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PLAFOND diet
Description: PLAFOND is a pragmatic patient-centered dietary intervention supported by dietitians who provide education and counseling in the form of Medical Nutrition Therapy (MNT) consisting of 0.6-0.8 g/kg/day dietary protein with \>2/3% of the protein from plant-proteins.
Study: NCT06015256

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: Blood sample (56mL) taken in a heparin tube

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: Blood sample (56mL) taken in a heparin tube

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: Blood sample (56mL) taken in a heparin tube

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: Blood sample (56mL) taken in a heparin tube
Study: NCT04990856

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Tumor blood flow after acute exercise